SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve who wrote (210)4/22/1998 4:47:00 PM
From: Russian Bear   of 496
 
Steve,

I thought the Gliadel numbers looked rather anemic, too. But Gliadel is really not that big a deal for Guilford, at least when compared to their potential big-market neurology drug projects.

I was gratified to learn that GLFD/AMGN were making progress with a lead neuroimunophilin ligand compound. I am not sure what, exactly, "additional pre-clinical research" means, but I do not think that it sounds ominous. I would expect that any compound, having undergone some pre-clinical testing, but not yet ready for an IND, would be in the "additional pre-clinical research" category.

I share your sentiments and hopes about Wall Street's foresight.

Regards,
RB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News